js016
mAbexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jun 5, 2020 (NCT04441918)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, passive
SARS-CoV-2 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05167279 | Phase 1 | Dec 17, 2021 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT04790786 | Phase 3 | Mar 10, 2021 | Berry Consultants, University of Pittsburgh |
| NCT04931238 | Phase 2 | Jan 20, 2021 | Chinese Academy of Medical Sciences |
| NCT04780321 | Phase 1/Phase 2 (Phase 2) | Oct 30, 2020 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT04441918 | Phase 1 | Jun 5, 2020 | Shanghai Junshi Bioscience Co.,Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Junshi Bioscience Co.,Ltd. | For profit | 3 | 3 | 2 | 2020 |
| Berry Consultants | For profit | 1 | 0 | 1 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1